Recommendations supporting respiratory syncytial virus vaccines marketed by Pfizer (NYSE:PFE) and GSK (NYSE:GSK) made last ...

The advisory panel to the Centers for Disease Control and Prevention had made recommendations regarding the use of separate ...

Pfizer (PFE) stock draws public scrutiny as a House probe gathers new allegations regarding the company's COVID-19 vaccine ...

An FDA panel of experts has recommended approval of Pfizer’s respiratory syncytial virus (RSV) vaccine in a pair of ... s RSVPreF3 jab will come under the scrutiny of the VRBPAC later today ...

GSK's vaccine against respiratory syncytial virus (RSV) is one of ... with the final results of Pfizer's study and as the data from both studies is subjected to scrutiny. The two companies say ...

Lawmakers are investigating whether Pfizer waited to share results of the Covid vaccine in 2020 until after that year’s presidential election, based on new allegations that a former Pfizer ...

Both subgroups cause disease and can co-circulate or alternate predominance from season to season. Pfizer currently is the only company with an RSV vaccine to help protect adults aged 60 and older, ...

WASHINGTON, May 15 (Reuters) - U.S. lawmakers on Thursday asked Pfizer Inc (PFE.N), opens new tab for information on alleged comments by a former executive suggesting its research executives ...

Key products like cardiovascular treatment Vyndaqel and the Prevnar 13 vaccine continue to drive growth, with non-COVID sales up 11% in the quarter. Pfizer’s pipeline is robust, with RSV vaccine ...